Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Seattle's Nautilus Biotechnology is laying off 16% of workforce, and plans to release its commercial platform in late 2026.

David Furnish’s leadership at EJAF proves brands can do more than raise awareness —they can dismantle stigma and drive ...

Salesforce is expected to report fourth-quarter results after the market closes Wednesday, with analysts largely bullish on ...

A common CV risk factor calculator for patients with HIV underestimates risk for Black patients and women, while risk for ...

Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report issued on Tuesday, February 25th. Zacks Research analyst E. Bagri ...

The Juilliard-trained talent said he's honored to get the gig: "Our queer siblings across the country who are being unfairly ...

Salesforce (CRM) reported fiscal fourth-quarter earnings and offered an outlook that fell short of analysts' expectations, ...

A new collaboration in the US between the Patient Advocate Foundation's (PAF) Patient Insight Institute, Gilead Sciences and ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the positions showed up on publicly available ...